Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

nuvalent inc - NUVL

NUVL

Close Chg Chg %
102.67 2.38 2.32%

Closed Market

105.05

+2.38 (2.32%)

Volume: 510.54K

Last Updated:

Jan 9, 2026, 4:00 PM EDT

Trade Now

Company Overview: nuvalent inc - NUVL

NUVL Key Data

Open

$103.45

 Day Range

103.42 - 106.10

52 Week Range

55.54 - 112.87

 Market Cap

$7.77B

Shares Outstanding

72.71M

 Public Float

47.70M

Beta

1.32

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$5.32

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

504.17K

  

NUVL Performance

1 Week
 
 4.17%
 
1 Month
 
 0.24%
 
3 Months
 
 19.24%
 
1 Year
 
 37.12%
 
5 Years
 
 N/A
 

NUVL Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 18
Full Ratings ➔

About nuvalent inc - NUVL

Nuvalent, Inc. is a clinical stage biopharmaceutical company, which focuses on creating precisely targeted therapies for patients with cancer. Its pipeline includes ROS1 NSCLC, ALK NSCLC and HER2 NSCLC. The company was founded by Matthew D. Shair in January 2017 and is headquartered in Cambridge, MA.

NUVL At a Glance

Nuvalent, Inc.
One Broadway
Cambridge, Massachusetts 02142
Phone 1-857-357-7000 Revenue 0.00
Industry Pharmaceuticals: Major Net Income -260,756,000.00
Sector Health Technology Employees 142
Fiscal Year-end 12 / 2025
View SEC Filings

NUVL Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio N/A
Price to Book Ratio 5.221
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -14.553
Enterprise Value to Sales N/A
Total Debt to Enterprise Value N/A

NUVL Efficiency

Revenue/Employee N/A
Income Per Employee -1,836,309.859
Receivables Turnover N/A
Total Asset Turnover N/A

NUVL Liquidity

Current Ratio 20.963
Quick Ratio 20.963
Cash Ratio 20.702

NUVL Profitability

Gross Margin N/A
Operating Margin N/A
Pretax Margin N/A
Net Margin N/A
Return on Assets -27.827
Return on Equity -29.458
Return on Total Capital -24.374
Return on Invested Capital -29.458

NUVL Capital Structure

Total Debt to Total Equity N/A
Total Debt to Total Capital N/A
Total Debt to Total Assets N/A
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital N/A
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Nuvalent Inc - NUVL

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
- - - -
-
Sales Growth
- - - -
-
Cost of Goods Sold (COGS) incl D&A
- - - -
-
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
- - - -
-
Depreciation
- - - -
-
Amortization of Intangibles
- - - -
-
COGS Growth
- - - -
-
Gross Income
- - - -
-
Gross Income Growth
- - - -
-
Gross Profit Margin
- - - -
-
2021 2022 2023 2024 5-year trend
SG&A Expense
45.82M 86.11M 149.49M 280.37M
Research & Development
35.56M 63.73M 113.24M 217.77M
Other SG&A
10.26M 22.38M 36.25M 62.59M
SGA Growth
+171.03% +87.94% +73.61% +87.55%
Other Operating Expense
- - - -
-
Unusual Expense
- - 635.00K 17.94M
-
EBIT after Unusual Expense
(46.45M) (86.11M) (149.49M) (298.31M)
Non Operating Income/Expense
114.00K 4.25M 23.27M 38.32M
Non-Operating Interest Income
- 4.25M 23.27M 38.32M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - -
-
Interest Expense Growth
- - - -
-
Gross Interest Expense
- - - -
-
Interest Capitalized
- - - -
-
Pretax Income
(46.34M) (81.85M) (126.22M) (259.99M)
Pretax Income Growth
-218.34% -76.65% -54.20% -105.98%
Pretax Margin
- - - -
-
Income Tax
- - - 764.00K
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(46.34M) (81.85M) (126.22M) (260.76M)
Minority Interest Expense
- - - -
-
Net Income
(46.34M) (81.85M) (126.22M) (260.76M)
Net Income Growth
-218.34% -76.65% -54.20% -106.59%
Net Margin Growth
- - - -
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(46.34M) (81.85M) (126.22M) (260.76M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(46.34M) (81.85M) (126.22M) (260.76M)
EPS (Basic)
-0.9594 -1.648 -2.1678 -3.9265
EPS (Basic) Growth
-218.21% -71.77% -31.54% -81.13%
Basic Shares Outstanding
48.30M 49.67M 58.22M 66.41M
EPS (Diluted)
-0.9594 -1.648 -2.1678 -3.9265
EPS (Diluted) Growth
-218.21% -71.77% -31.54% -81.13%
Diluted Shares Outstanding
48.30M 49.67M 58.22M 66.41M
EBITDA
(45.82M) (86.11M) (149.49M) (280.37M)
EBITDA Growth
-171.03% -87.94% -73.61% -87.55%
EBITDA Margin
- - - -
-

Snapshot

Average Recommendation BUY Average Target Price 141.706
Number of Ratings 18 Current Quarters Estimate -1.454
FY Report Date 03 / 2026 Current Year's Estimate -5.769
Last Quarter’s Earnings -1.452 Median PE on CY Estimate N/A
Year Ago Earnings -5.715 Next Fiscal Year Estimate -4.244
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 12 12 17 16
Mean Estimate -1.45 -1.50 -5.77 -4.24
High Estimates -1.27 -1.26 -4.81 -1.45
Low Estimate -1.57 -1.62 -6.59 -6.64
Coefficient of Variance -6.08 -6.35 -9.47 -37.60

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 15 15 13
OVERWEIGHT 3 3 3
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Nuvalent Inc - NUVL

Date Name Shares Transaction Value
Dec 12, 2025 Ron Squarer Director 4,418 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Dec 12, 2025 Ron Squarer Director 2,837 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 18, 2025 James R. Porter President and CEO; Director 276,062 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $27.85 per share 7,688,326.70
Apr 18, 2025 James R. Porter President and CEO; Director 265,075 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $68.31 per share 18,107,273.25
Apr 18, 2025 James R. Porter President and CEO; Director 254,015 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $69.05 per share 17,539,735.75
Apr 18, 2025 James R. Porter President and CEO; Director 249,550 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $70.05 per share 17,480,977.50
Apr 18, 2025 James R. Porter President and CEO; Director 249,062 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $70.73 per share 17,616,155.26
Apr 18, 2025 James R. Porter President and CEO; Director 231,780 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 11, 2025 Darlene Noci Chief Development Officer 74,356 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $70.65 per share 5,253,251.40
Mar 11, 2025 Darlene Noci Chief Development Officer 10,216 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 11, 2025 Darlene Noci Chief Development Officer 6,776 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 11, 2025 Darlene Noci Chief Development Officer 14,216 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 11, 2025 Darlene Noci Chief Development Officer 48,034 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $72.59 per share 3,486,788.06
Mar 11, 2025 Darlene Noci Chief Development Officer 49,134 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $71.68 per share 3,521,925.12
Mar 11, 2025 Darlene Noci Chief Development Officer 52,034 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $1.08 per share 56,196.72
Mar 11, 2025 Darlene Noci Chief Development Officer 48,034 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $72.6 per share 3,487,268.40
Mar 11, 2025 Darlene Noci Chief Development Officer 52,340 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $71.92 per share 3,764,292.80
Mar 11, 2025 Darlene Noci Chief Development Officer 78,034 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $6.89 per share 537,654.26
Mar 11, 2025 Darlene Noci Chief Development Officer 70,019 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $1.08 per share 75,620.52
Feb 26, 2025 Matthew D. Shair Director 218,206 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $77.51 per share 16,913,147.06

Nuvalent Inc in the News